AustraliaHealth

Echo IQ (ASX:EIQ) executed an exclusive agreement to license up to 1 million de-identified echocardiography studies from Advara HeartCare.

Genetic Signatures (ASX:GSS) received no advance notification regarding a 10.2% stake acquisition by BCAL Diagnostics (ASX:BDX).

Imugene (ASX:IMU) announced a second complete response within 24 hours in its concurrent combination trial cohort.

Telix Pharmaceuticals (ASX:TLX) aligned with the US regulator to advance its Phase 3 trial after a 36-patient safety study.

Cyclopharm (ASX:CYC) defers short-term US installation guidance due to delayed clinical guidelines, despite reporting preliminary global revenue of $17.1 million.

Osteopore (ASX:OSX) has completed the development project for its intra-operative external ventricular drain guide.

Algorae Pharmaceuticals (ASX:1AI) has secured a three-year public hospital supply contract with NSW Health.

Enlitic (ASX:ENL) signed a three-year Ensight subscription contract worth $359,000 with Lumus Imaging to enter the Australian market.

Inoviq (ASX:IIQ) alters its EXO-OC ovarian cancer test development pathway after sample degradation in a 1,200-sample study renders them unsuitable for evaluation.

Biome Australia (ASX:BIO) has reported a 30% increase in preliminary annual sales revenue to $23.9 million for FY26.

Imugene (ASX:IMU) announced that the first patient in its azer-cel Phase 1b trial cohort achieved a complete response.

Recce Pharmaceuticals (ASX:RCE) has secured firm commitments to raise $4 million through a new institutional share placement.